This study looks at how a medicine called **benralizumab** affects people with **severe eosinophilic asthma**. Eosinophilic asthma is a type of asthma where there are high numbers of white blood cells called eosinophils in the lungs, which can make breathing difficult. The study lasts for 48 weeks, where participants continue their regular asthma medication, including **inhaled corticosteroids (ICS)** and **long-acting beta-agonists (LABA)**, while adding benralizumab.

After completing treatment, there is a 4-week follow-up. To join, you must be between 18 and 70 years old and already on high-dose ICS and LABA for at least 3 months. You also need to have certain lung function levels and eosinophil counts. Pregnant or breastfeeding women, smokers, or people with certain other health conditions can't join.

• The study lasts 52 weeks in total (48 weeks treatment + 4 weeks follow-up).
• Participants must have persistent asthma despite standard treatment.
• Some health conditions and previous treatments may disqualify you.